IKK classic Secures €224.6 Million Framework for Pharmaceutical Discount Agreements Across 257 Lots

A massive procurement for pharmaceutical discount agreements worth over €224.6 million has been awarded by IKK classic. The contract, spanning 257 lots with multiple winners including BG ALIUD/STADAPHARM, BG Hexal/1 A Pharma, BG TEVA/ratiopharm, and numerous other pharmaceutical companies, demonstrates how German statutory health insurers are securing cost-effective medicine supply through competitive tender processes.

Introduction

Every day, millions of people in Germany rely on prescription medications. Statutory health insurance funds like IKK classic must ensure that their members have access to high-quality, cost-effective pharmaceuticals. IKK classic has taken a significant step to achieve this by awarding a comprehensive procurement for discount agreements covering 257 pharmaceutical active ingredients and combinations.

While not a headline-grabbing consumer deal, this procurement is fundamental to ensuring that IKK classic's members have access to affordable medications. It reveals a great deal about how German statutory health insurers manage pharmaceutical procurement through competitive tendering.

Why This Contract Matters

Under German social security law (§ 130a Abs. 8 SGB V), statutory health insurance funds are required to conclude discount agreements with pharmaceutical manufacturers for prescription medicines. These agreements allow insurers to secure cost savings that help keep healthcare contributions stable.

IKK classic is one of Germany's largest statutory health insurance funds, serving over 2 million members nationwide. This procurement covers a wide range of active ingredients, from common medications like acetylsalicylic acid and metformin to specialised treatments for rare diseases.

Contract Timeline

• Contract award notice published: 29 July 2026 (OJ S 144/2026)
• Contracts concluded: 8 July 2026
• Regular contract start date: 1 January 2027
• Regular contract end date: 31 December 2028
• Special lots (005, 011, 016, 031, 034, 040, 042, 065, 083, 090, 096, 098, 107, 110, 119, 122, 129, 139, 142, 144, 150, 152, 162, 173, 177, 180, 202, 204, 208, 216, 236, 237): Start 1 October 2026, duration 27 months

Contract Overview

IKK classic conducted an open procedure for the conclusion of discount agreements according to § 130a Abs. 8 SGB V. The procurement is divided into 257 lots, each covering a specific active ingredient or active ingredient combination. Contracts are awarded to a maximum of one, two, or three pharmaceutical companies per lot, depending on the product category.

The total value of all contracts awarded is €224,584,123. The regular contract duration is 2 years (1 January 2027 – 31 December 2028), with a special provision allowing IKK classic to extend the agreement for up to 12 months by unilateral declaration. For 32 specified lots, the contract begins earlier (1 October 2026) and has a 27-month duration.

Key Contract Details

Detail	Information
Contracting Authority	IKK classic
Contract Subject	Pharmaceutical products (CPV 33600000)
Procedure Type	Open procedure
Legal Basis	Directive 2014/24/EU, VgV, SGB V § 130a Abs. 8
Total Value of Contracts Awarded	€224,584,123.00
Number of Lots	257
Contract Duration	2 years (1 Jan 2027 – 31 Dec 2028) with 1 x 12-month extension option; 32 lots: 27 months (1 Oct 2026 – 31 Dec 2028)
Award Criteria	Price (lowest total price)
EU Funding	None disclosed
Covered by GPA	Yes
Review Organisation	Bundeskartellamt - Vergabekammer des Bundes

Selected Lots and Winners (Representative Sample)

Lot	Active Ingredient	Max Partners	Winners	Value (€)
001	Acetylsalicylsäure magensaftresistente Tabletten u.w.	3	BG ALIUD/STADAPHARM, BG Hexal/1 A Pharma, Dexcel Pharma	662,842
002	Agomelatin Filmtabletten	3	Glenmark, neuraxpharm, Zentiva	489,005
003	Alendronsäure Tabletten u.w.	2	BG Heumann/Heunet, Bluefish Pharma	847,633
004	Allopurinol Tabletten	3	BG ALIUD/STADAPHARM, BG Heumann/Heunet, HEC Pharm	950,165
005	Amifampridin Tabletten	1	Hormosan Pharma	427,767
006	Amisulprid Filmtabletten	2	Holsten Pharma, Viatris Healthcare	272,927
007	Amisulprid Tabletten	3	Holsten Pharma, PUREN Pharma, Viatris Healthcare	443,988
008	Amitriptylin Filmtabletten u.w.	2	Amarox Pharma, BG Neuraxpharm/Hexal	689,008
009	Amlodipin Tabletten	3	BG Hexal/1 A Pharma, BG TEVA/ratiopharm, Zentiva	1,652,640
010	Anagrelid Hartkapseln	2	BG Heumann/Heunet, HIKMA PHARMA	455,487
011	Apremilast Filmtabletten	3	089Pharm, Macleods Pharma, Zentiva	866,300
012	Aprepitant Hartkapseln	2	BG Hexal/1 A Pharma, BG TEVA/ratiopharm	138,588
013	Atenolol Filmtabletten u.w.	2	BG Heumann/Heunet, BG TEVA/ratiopharm	68,962
014	Atomoxetin Hartkapseln	3	Amarox Pharma, PUREN Pharma, Zentiva	421,487
015	Atorvastatin + Ezetimib Filmtabletten u.w.	2	BG Heumann/Heunet, Zentiva	2,722,952
016	Atovaquon Suspension zum Einnehmen	1	Glenmark	98,025
017	Azathioprin Filmtabletten u.w.	2	BG Heumann/Heunet, BG Hexal/1 A Pharma	617,329
018	Azelastin + Fluticason Nasenspray	1	BG Hexal/1 A Pharma	240,653
019	Betamethason + Salicylsäure Salbe	1	Klinge Pharma	156,449
020	Betamethason Creme	1	No winner	-
021	Betamethason Emulsion	1	No winner	-
022	Betamethason Lösung	1	No winner	-
023	Betamethason Salbe	1	No winner	-
024	Bicalutamid Filmtabletten	2	BG Hexal/1 A Pharma, PUREN Pharma	384,408
025	Bimatoprost + Timolol EDO	2	BG ALIUD/STADAPHARM, Micro Labs	413,198
026	Bimatoprost EDO	1	BG ALIUD/STADAPHARM	288,667
027	Bisoprolol + Hydrochlorothiazid Filmtabletten	2	BG Hexal/1 A Pharma, BG TEVA/ratiopharm	321,627
028	Bisoprolol Filmtabletten u.w.	3	BG TEVA/ratiopharm, Zentiva	2,507,223
029	Bosentan Filmtabletten	2	BG Heumann/Heunet, PUREN Pharma	1,697,386
030	Brinzolamid Augentropfen	2	BG Heumann/Heunet, Micro Labs	607,346
031	Budesonid Hartkapseln mit veränderter Wirkstofffreisetzung	1	Medical Valley Invest	298,162
032	Budesonid Suspension für einen Vernebler	2	BG ALIUD/STADAPHARM	495,424
033	Buprenorphin + Naloxon Sublingualtabletten	1	ETHYPHARM	34,183
034	Buprenorphin Pflaster transdermal Tragedauer 3 Tage	1	No winner	-
035	Bupropion Tabletten mit veränderter Wirkstofffreisetzung	3	Accord Healthcare, Basics, BG Hexal/1 A Pharma	2,520,709

Winning Bidders Summary

The procurement attracted a wide range of pharmaceutical companies, from global giants to specialised manufacturers. The most successful bidders included:

Bidder/Consortium	Number of Lots Won	Key Products
BG Hexal / 1 A Pharma GbR	60+	Wide range including cardiovascular, CNS, and generic products
BG ALIUD / STADAPHARM GbR	40+	Wide range including cardiovascular, diabetes, and CNS products
BG TEVA / ratiopharm GbR	40+	Wide range including cardiovascular, CNS, and generic products
BG Heumann / Heunet GbR	30+	Wide range including cardiovascular, urology, and generic products
Zentiva Pharma GmbH	20+	Cardiovascular, CNS, and generic products
PUREN Pharma GmbH & Co. KG	20+	Cardiovascular, CNS, and generic products
Glenmark Arzneimittel GmbH	10+	CNS, cardiovascular, and specialty products
neuraxpharm Arzneimittel GmbH	10+	CNS, pain management, and specialty products
Viatris Healthcare GmbH	10+	Cardiovascular, CNS, and generic products

About the Contracting Authority

IKK classic is one of Germany's largest statutory health insurance funds, serving over 2 million members nationwide. As a public corporation under social security law, IKK classic is responsible for providing health insurance coverage to its members, including access to prescription medications. The fund is committed to ensuring cost-effective, high-quality healthcare for its members through competitive procurement and efficient administration.

About the Winning Bidders

The procurement attracted a diverse range of pharmaceutical companies:

• BG Hexal / 1 A Pharma GbR: A leading generic pharmaceutical consortium, part of the Sandoz/Hexal group, one of the world's largest generic manufacturers.
• BG ALIUD / STADAPHARM GbR: A consortium of two major German generic pharmaceutical companies, offering a broad portfolio of high-quality generics.
• BG TEVA / ratiopharm GbR: A consortium of Teva (the world's largest generic manufacturer) and ratiopharm (one of Germany's leading generic companies).
• BG Heumann / Heunet GbR: A consortium of Heumann Pharma and Heunet Pharma, specialising in generics and specialty pharmaceuticals.
• Zentiva Pharma GmbH: A leading European pharmaceutical company with a strong focus on generics and over-the-counter products.
• PUREN Pharma GmbH & Co. KG: A German pharmaceutical company specialising in generics and specialty products.

Procurement Analysis

Procedure: An open procedure was used, following the German VgV (Procurement Regulation). The procurement was divided into 257 lots, with bidders able to submit offers for any number of lots. Contracts were awarded based on price alone.

Competition: Competition levels varied significantly by lot, with some lots receiving multiple bids and others receiving none. Several lots (020-023, 034, 047, 097, 110, 119, 129, 173, 180, 236, 237) received no bids and were closed without a winner.

Award Criteria: Price was the sole award criterion, with contracts awarded in ascending order of total price. This reflects the nature of pharmaceutical discount agreements, where the primary objective is to secure the lowest possible cost for medications.

Lot Structure: The procurement was divided into 257 active ingredient-based lots, allowing pharmaceutical companies to bid on specific product categories where they have competitive advantages. The maximum number of partners per lot varied from one to three, ensuring a balance between competition and administrative efficiency.

Sanctions Compliance: The tender included provisions requiring compliance with EU sanctions (Regulation 2022/576, Article 5k) regarding Russian involvement, reflecting the EU's sanctions regime following Russia's actions in Ukraine.

GPA Status: The procurement is covered by the World Trade Organization's Government Procurement Agreement (GPA), meaning it was, in principle, open to qualifying international bidders.

Additional Procurement Facts

• The procurement covers 257 lots with a total value of over €224.6 million.
• Contracts were awarded to a maximum of one, two, or three pharmaceutical companies per lot.
• Several lots received no bids and were closed without a winner.
• The majority of winners are German-based companies or consortia.
• Bidder consortia (Bietergemeinschaften) were common, allowing companies to combine their product portfolios.
• Each contract includes a 1 x 12-month extension option.
• No EU funding was used for this procurement.
• Disputes or review requests fall to the Bundeskartellamt - Vergabekammer des Bundes.

Market & Industry Perspective

The German pharmaceutical discount agreement market is one of the largest and most competitive in the world. Statutory health insurance funds like IKK classic use competitive tendering to secure cost savings on prescription medications, which helps keep healthcare contributions stable.

The price-only award criterion reflects the nature of discount agreements, where the primary objective is to secure the lowest possible cost for medications. Quality and safety are assured through regulatory requirements, including marketing authorisation and pharmaceutical quality standards.

The high number of lots (257) allows for granular competition on individual active ingredients, enabling smaller and specialised manufacturers to compete alongside large generic companies.

Economic Significance

At over €224.6 million, this procurement represents a significant portion of IKK classic's pharmaceutical expenditure. The discount agreements secured through this tender will generate substantial cost savings for the health insurance fund, helping to keep healthcare contributions stable for its over 2 million members.

For the winning pharmaceutical companies, the contracts provide guaranteed volume and revenue stability over the 2-year (or 27-month) contract period.

Future Procurement Opportunities

This procurement covers discount agreements through the end of 2028 (and into 2029 with the extension option). Future procurement opportunities may include:

• Renewal of these agreements for the next contract period
• Additional active ingredients not covered in this tender
• Other pharmaceutical categories (e.g., biosimilars, specialty medicines)
• Contracts with other statutory health insurance funds

Opportunities for Suppliers

Pharmaceutical companies active in the German market should note the scale and importance of discount agreement tenders. The price-based award criteria require competitive pricing, but companies must also demonstrate the ability to reliably supply medications over the contract period.

Key success factors include: competitive pricing, reliable supply chain, ability to offer a broad portfolio of products, and compliance with regulatory requirements.

What Businesses Should Watch

• Future discount agreement tenders from IKK classic and other statutory health insurance funds.
• Changes in pharmaceutical regulations and reimbursement frameworks.
• Market entry of new generic and biosimilar products.
• Opportunities for consortium bidding with other pharmaceutical companies.

GermanyTender Procurement Intelligence

This contract is a significant case study in how German statutory health insurance funds manage pharmaceutical procurement. IKK classic has secured a €224.6 million framework for discount agreements, with numerous pharmaceutical companies selected through a competitive open procedure.

The most notable feature of this tender is the scale and granularity of the procurement, with 257 active ingredient-based lots. This approach enables IKK classic to secure competitive pricing on a wide range of medications while allowing pharmaceutical companies to bid on specific product categories where they have competitive advantages.

The price-only award criterion reflects the nature of discount agreements, where the primary objective is to secure the lowest possible cost for medications. Quality and safety are assured through regulatory requirements, including marketing authorisation and pharmaceutical quality standards.

The consortium structure of many bidders (Bietergemeinschaften) is an interesting feature of this market. By forming consortia, pharmaceutical companies can combine their product portfolios to offer comprehensive coverage across multiple lots, increasing their chances of winning contracts.

The 32 lots with earlier start dates (1 October 2026) and 27-month durations reflect specific market needs and provide longer-term stability for certain products.

For suppliers, the lesson is that competitive pricing is essential, but the ability to reliably supply high-quality medications over the contract period is equally important. Companies that can demonstrate both are best positioned for these contracts.

Supplier Takeaways

• Price is the sole award criterion; competitive pricing is essential.
• Consortium bidding allows companies to combine product portfolios.
• Reliable supply chains and regulatory compliance are critical.
• The 257-lot structure enables participation from companies of all sizes.
• Contracts offer 2-year (or 27-month) revenue stability with extension options.
• Sanctions compliance (EU Regulation 2022/576) is mandatory.

Key Takeaways

• IKK classic awarded a €224.6 million pharmaceutical discount agreement procurement across 257 lots.
• Major winners include BG Hexal/1 A Pharma, BG ALIUD/STADAPHARM, BG TEVA/ratiopharm, and BG Heumann/Heunet.
• Award criteria: Price (lowest total price).
• Contracts have a 2-year duration with 1 x 12-month extension option.
• 32 lots have an earlier start date (1 October 2026) and 27-month duration.
• The procurement ensures cost-effective medication supply for over 2 million IKK classic members.

Conclusion

This is not a contract that will make national headlines, but it reflects something structurally important about how Germany manages pharmaceutical procurement. By awarding a €224.6 million framework for discount agreements across 257 lots, IKK classic ensures that its over 2 million members have access to cost-effective medications. The contract demonstrates the importance of competitive tendering, the value of granular lot structures, and the critical role of pharmaceutical discount agreements in maintaining affordable healthcare in Germany.

Frequently Asked Questions

Q: What is IKK classic?

It is one of Germany's largest statutory health insurance funds, serving over 2 million members nationwide.

Q: What are pharmaceutical discount agreements?

Under § 130a Abs. 8 SGB V, statutory health insurance funds must conclude discount agreements with pharmaceutical manufacturers to secure cost savings on prescription medications.

Q: How many lots were in this procurement?

The procurement was divided into 257 lots, each covering a specific active ingredient or active ingredient combination.

Q: What is the value of this procurement?

The total value of all contracts awarded is €224,584,123.

Q: Is this contract funded by the EU?

No. The notice confirms the project is not financed with EU funds, though it is governed by EU Directive 2014/24/EU.

Source: EU Official Journal, Contract Award Notice 524009-2026, OJ S 144/2026, published 30 July 2026.